AP 2200Alternative Names: AP2200
Latest Information Update: 03 Jun 2016
At a glance
- Originator Arissa Pharma
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Pain
Most Recent Events
- 03 Jun 2016 Phase-I clinical trials in Pain (In volunteers) (PO) before June 2016